Express Pharma

MARCH 31, 2025

This is different from traditional chemotherapy which is usually given orally and intravenously. It was launched in 2004 with a $22 million endowment from Mark and Mary Stevens. Researchers completed phase 1 clinical trials demonstrating safety and tolerance to NEO100 in 2019.

Chemotherapy 66

Chemotherapy 66

The Thyroid Pharmacist

NOVEMBER 4, 2022

A study in 2004 found that there is an association between the presence of an anxiety or mood disorder, and the presence of TPO antibodies. (33) Selenium may also interact with other supplements and medications, such as cholesterol-lowering statin drugs, antacids, chemotherapy drugs, corticosteroids, niacin, and even birth control pills.

Diabetes 98

Diabetes Dosage Compounding Immunity 98

European Pharmaceutical Review

JULY 5, 2022

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. Benefits of daily oral chemotherapy over IV.

Chemotherapy 104

Chemotherapy Dosage Labelling Compounding 104

pharmaphorum

JANUARY 19, 2022

EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone. But prevalence still increased by 10% between 2008 and 2012.

Chemotherapy 59

Chemotherapy Immunity Immunization 59

The Thyroid Pharmacist

JULY 8, 2022

Interestingly, a 2004 study found an association between the presence of an anxiety or mood disorder, and the presence of thyroid peroxidase (TPO) antibodies. (4). Published 2004 Aug 18. 2004 Jun;18(2):303-16. I remember my own disbelief when, after taking selenium supplements, my frequent panic attacks completely disappeared!

Dosage 59

Dosage Immunity Immunization Diabetes 59

European Pharmaceutical Review

JULY 26, 2022

The committee has recommended that Rubraca (rucaparib camsylate) should no longer be used as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation in patients whose cancer has come back after at least two platinum-based chemotherapies and who cannot have further platinum-based therapy.

Vaccines 105

Vaccines Diabetes Chemotherapy 105